Blood test may help doctors switch cancer treatment earlier

NCT ID NCT05826964

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether a blood test that tracks tumor DNA (ctDNA) can help doctors switch treatments earlier in people with metastatic breast cancer. The goal is to see if acting on a molecular signal of progression, before symptoms or scans show it, can keep the cancer under control longer. About 24 participants will be randomly assigned to switch therapy early based on ctDNA levels or wait for standard signs of progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Aromatase inhibitor (AI) or selective estrogen receptor degrader (SERD) plus a CDK4/6 inhibitor
What this could lead to
If successful, this could show that using a blood test to detect early molecular changes allows doctors to switch treatments sooner, potentially keeping metastatic breast cancer under control for longer.
What could go wrong
This is a small, early-phase study (24 people) testing a monitoring strategy, not a new drug. The approach may not improve outcomes or could lead to unnecessary treatment switches.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Miami

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.